Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 1 - Drugs for disorders of the alimentary tract or the digestive system
Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798)
10/2003
10/22/2003CN1124855C Pharmaceutical compositions, based on etheric oils obtained from plants for use in the human and verterinary medical field
10/22/2003CN1124854C Chinese medicine for curing gastnopathy
10/21/2003US6635786 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use
10/21/2003US6635764 Urea compounds that are muscarinic receptor antagonists and agonists, administering to the mammal the urea compound to treat urinary incontinence, chronic pulmonary obstructive disease, asthma, hyper salivation, blurred vision etc.
10/21/2003US6635762 Monocyclic-7H-pyrrolo[2,3-d]pyrimidine compounds, compositions, and methods of use
10/21/2003US6635680 Controlled release pellet formulation
10/21/2003US6635678 Topical application of phenylephrine
10/21/2003US6635673 1-Aminomethyl-3,4-dimethyl-cyclopentyl acetic acid; epilepsy; neurodegenerative, neuropathological and gastrointestinal disorders; depression, anxiety, panic, pain
10/21/2003US6635671 Compounds which affect mRNA stability and uses therefor
10/21/2003US6635658 Amino-tetralin derivatives as muscarinic receptor antagonists
10/21/2003US6635645 2,5,-diazabicyclo[2.2.1]heptane derivatives, their preparation and therapeutic uses
10/21/2003US6635644 Pyrimido(1,6-b)pyridazine derivatives used as p38 inhibitors a mammalian protein kinase is involved in cell proliferation, cell death and response to extracellular stimuli
10/21/2003US6635643 For treating conditions which are related to impairment of gastric emptying
10/21/2003US6635642 Poly(ADP-ribose) polymerase inhibitors; tissue damage treatment
10/21/2003US6635637 Cyclic oxyguanidine protease inhibitors
10/21/2003US6635431 Recombinant lipolysis stimulated (LSR) comprising polypeptide of given sequence; use for selecting a compound for enhancing lipoprotein uptake in cells expressing the polypeptide
10/21/2003US6635288 Pulverizing in solvent; therapy for liver disorders
10/21/2003US6635252 Antibodies to superoxide dismutase-4
10/21/2003CA2117883C Erythromycin derivatives
10/16/2003WO2003085728A1 Carrier, method of manufacturing a carrier and an electronic device
10/16/2003WO2003085110A2 Oligomeric compounds for the modulation hif-1alpha expression
10/16/2003WO2003085072A1 Method for obtaining ozonized oils and vegetable fats and use of said products for pharmaceutical and cosmetic purposes
10/16/2003WO2003084966A1 Oxazolidinone derivatives
10/16/2003WO2003084964A1 1-oxa-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the production thereof
10/16/2003WO2003084961A1 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
10/16/2003WO2003084956A1 Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same
10/16/2003WO2003084955A1 Diazabicyclo alkane derivatives with nk1 antagonistic activity
10/16/2003WO2003084954A1 Tropane derivatives as ccr5 modulators
10/16/2003WO2003084953A1 6-(4-substituted-anilino)pyrimidine derivatives, method for the preparation thereof and antiviral pharmaceutical composition comprising the same
10/16/2003WO2003084952A1 Benzoxazinone-derived compounds, their preparation und use as medicaments
10/16/2003WO2003084951A1 (3z) -3-(3-hydro-isobenzofuran-1-ylidene)-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
10/16/2003WO2003084943A2 Terphenyl derivatives, preparation thereof, compositions containing same
10/16/2003WO2003084941A2 Hydroxamic acid derivatives
10/16/2003WO2003084940A1 Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
10/16/2003WO2003084939A1 Benzoxazinone derivatives, the preparation and use thereof as medicaments
10/16/2003WO2003084938A2 Pyrimidone derivatives useful for the treatment of inflammatin and immunological diseases
10/16/2003WO2003084937A2 Pyrimidinedione derivatives useful for the treatment of inflammation and immunological diseases
10/16/2003WO2003084936A2 Amino substituted pyrimidinone derivatives useful in the treatment of inflammation and immunological
10/16/2003WO2003084935A2 Diaryl pyrimidinone derivatives useful for the treatment of inflammation and immunogolical diseases
10/16/2003WO2003084915A1 Novel thyroid receptor ligands
10/16/2003WO2003084560A2 Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis
10/16/2003WO2003084556A1 Process for producing fat composition containing hydrophobic components of glycyrrhiza
10/16/2003WO2003084555A1 Compositions for inhibiting fibrosis
10/16/2003WO2003084537A1 Therapeutic agent for food competence disorder in stomach
10/16/2003WO2003084527A1 Severe sepsis preventive therapeutic agent
10/16/2003WO2003084524A1 Combination therapy for the treatment of conditions with pathogenic inflammatory components
10/16/2003WO2003084521A2 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
10/16/2003WO2003084344A2 Method of improving absorption of vitamin e by a pet animal
10/16/2003WO2003084343A2 Method and dietary composition for improving fat digestibility
10/16/2003WO2003084342A2 Method and dietary composition for improving lipid digestibility
10/16/2003WO2003064407A3 Production of δ9 tetrahydrocannabinol
10/16/2003WO2003061620A3 Peptide-carrying bodies for immune response
10/16/2003WO2003039231A3 Compounds and methods for treating transplant rejection
10/16/2003WO2003035835A3 Glycoprotein compositions
10/16/2003WO2003033527A3 Cyclosporine analogue mixtures and their use as immunomodulating agents
10/16/2003WO2003026743A3 Opioid formulations having reduced potential for abuse
10/16/2003WO2003015494A3 Tocopherol enriched compositions and amelioration of inflammatory symptoms
10/16/2003WO2003008407A3 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
10/16/2003WO2002100849A3 Novel nitriles useful as reversible inhibitors of cysteine proteases
10/16/2003WO2002100826A3 Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
10/16/2003WO2002100347A3 Prodrugs of gaba analogs, compositions and uses thereof
10/16/2003WO2002093176A3 Methods for identifying compounds for treatment of ibd
10/16/2003WO2002085299A3 Therapeutic treatments using the direct application of antimicrobial metal compositions
10/16/2003WO2002068677A8 Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
10/16/2003WO2002042484A3 Method for producing pectin hydrolysis products
10/16/2003WO2002036151A3 Use of the long pentraxin ptx3 for the preparation of medicament for the prevention and cure of autoimmune pathologies
10/16/2003WO2002036118A3 Heterocyclic derivatives useful as pharmaceutical agents
10/16/2003WO2002007673A3 Calcilytic compounds
10/16/2003US20030195352 For therapy of diabetes, obesity, impaired glucose tolerance, gastrointestinal disorders, hypertriglyceridemia, hypercholesteolemia, atherosclerotic disorders, or cardiovascular disorders
10/16/2003US20030195343 Process for producing erythromycin derivative
10/16/2003US20030195261 Administering racemic or optically pure sibutramine metabolite, or a pharmaceutically acceptable salt, solvate, or clathrate for prophylaxis or therapy
10/16/2003US20030195257 Compounds useful for the preparation of medicaments with phosphodiesterase IV inhibitory activity
10/16/2003US20030195251 For therapy of psychiatric, pain and other disorders
10/16/2003US20030195241 Mitogen-activated protein kinase inhibitors used for prophylaxis of cancer, inflammatory and cardiovascular disorders, and as coatings for medical equipments such as stents
10/16/2003US20030195240 Synergystic mixtures of proton pump inhibitors and nitrogen compounds such as 5-((2-adamantan-1-ylmethyl-5-phenyl-1H-pyrole-3-carbonyl)amino)-isophthalic acid, used for prophylaxis of gastrointerstinal disorders
10/16/2003US20030195237 Gastrin and cholecystokinin receptor lignads (iv)
10/16/2003US20030195235 Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
10/16/2003US20030195230 Substituted amine derivatives and methods of use
10/16/2003US20030195228 Pharmaceutical compositions for hepatitis C viral protease inhibitors
10/16/2003US20030195226 Nitrogen compounds such as pyridine-3-carbaldehyde, O-(((4-undecyloxy-phenyl)amino)carbonyl)oxime, used for prophylaxis of vision, eating or cardiovascular disorders, and as anxiolytic and antiemetic agents
10/16/2003US20030195222 Substituted pyrimidinones and pyrimidinthiones
10/16/2003US20030195221 Substituted indolizine-like compounds and methods of use
10/16/2003US20030195214 Cancer treatment
10/16/2003US20030195212 An amide derivatives for treating obesity, anorexia, inflammation, mental diseases associated with the melanocyte stimulating hormones
10/16/2003US20030195211 Inhibitors of human phosphatidylinositol 3-kinase delta
10/16/2003US20030195206 An enzyme inhibitors, enzyme is to catalyse the hydrolysis of an ester; treating hyperlipaemia, hyperglycaemia (type II diabetes), hypertension, cardiovascular disorders stroke, gastrointestinal disease; chemical intermediate synthesis
10/16/2003US20030195201 Vanilloid receptor ligands and their use in treatments
10/16/2003US20030195194 For therapy of immune related responses, tumor growth, glomerulonephritis, inflammation, malarial anemia, septic shock, tumor associated angiogenesis, vitreoretinopathy, psoriasis, graft versus host disease, atopic dermatitis
10/16/2003US20030195188 Pyridine and quinoline derivatives
10/16/2003US20030195181 Laulimalide derivatives
10/16/2003US20030195179 Redispersibility comprising polyvinylpyrrolidone and a water-soluble anionic macromolecular compound which are added to prevent a hardly soluble drug from adhering to a container and forming aggregates
10/16/2003US20030195175 Use of carbon-2-modified-vitamin D analogs to induce the formation of new bone
10/16/2003US20030195171 Method for inhibiting bone resorption with an alendronate and vitamin D formulation
10/16/2003US20030195169 Such as (S)-phosphoric acid mono-(3-(5-chloro-2-methoxy-phenyl)-3-fluoro-2-oxso-6-trifluoromethyl-2,3 -dihydro-indol-1-ylmethyl)ester; for modulation of large-conductance calcium-activated potassium (BK) channels
10/16/2003US20030195160 Sodium channel blockers
10/16/2003US20030194761 Novel nucleic acid sequences encoding human fibroblast growth factor-like polypeptides
10/16/2003US20030194720 Human ion channels
10/16/2003US20030194719 Tpst-assay for diagnosis of autism and related disorders
10/16/2003US20030194456 Extract of the leaves and/or stem of Argemone mexicana plant for treatment of psoriasis and related biochemical and immunological disorders
10/16/2003US20030194451 Crude drug composition for preventing and treating gastrointestinal dyskinetic diseases
1 ... 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 ... 1258